

BULLETIN FROM EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 3 July 2023, Q-linea AB (publ) (the “Company”) held an extraordinary general meeting in Uppsala, whereby the resolutions below were adopted.

The general meeting was held at Hubben on Dag Hammarskjölds väg 38 in Uppsala. For more detailed information on the content of the resolutions, please see the complete notice of the extra general meeting that is available on the Company’s website, www.qlinea.com. Minutes from the extra general meeting will be provided on the said website within two weeks from the day of the meeting.

Adoption on new articles of association

The general meeting resolved to adopt new articles of association in accordance with the board’s proposal, entailing an amendment of the limits of the share capital and the number of shares.

· The limits of the share capital in §4 is amended, entailing the following wording:

The share capital shall be at least 5,750,000 and maximum 23,000,000 SEK.

· The limits of the numbers of shares in §5 is amended, entailing the following wording:

The number of shares shall be at least 115,000,000 and maximum 460,000,000.

The general meeting’s subsequent approval of the board’s resolution on 1 June 2023 regarding the issue of new common shares with preferential rights for existing shareholders

The general meeting resolved to approve the board’s resolution on a rights issue which was resolved on by the board on 1 June 2023.

The preferential share issue includes a share issue of not more than 87,628,425 new common shares which entails an increase of the Company’s share capital with not more than SEK 4,381,421.25. The right to subscribe for new common shares shall belong to those persons who on the record date for the new issue of shares are recorded as shareholders of the Company, where one (1) existing share shall entitle to three (3) new common shares (i.e. a subscription ration of 3:1). Should all new shares not be subscribed based on subscription rights, the board shall resolve on the allocation of new shares without subscription rights according to certain principles described in the notice to the general meeting, where allocation is ultimately made to those who have entered into guarantee commitments.

The new shares are issued at a subscription price of SEK 3 per share. The record date for participation in the new issue shall be 5 July 2023.

All resolutions by the general meeting were adopted by the required majority.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

BULLETIN FROM EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)